The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by Leerink Partners on July 6, 2026. The analyst firm set a price target for $38.00 expecting AVTX to rise to within 12 months (a possible 101.70% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Avalo Therapeutics (NASDAQ:AVTX) was provided by Leerink Partners, and Avalo Therapeutics initiated their outperform rating.

The last upgrade for Avalo Therapeutics Inc happened on April 16, 2024 when Oppenheimer raised their price target to $35. Oppenheimer previously had a perform for Avalo Therapeutics Inc.

There is no last downgrade for Avalo Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on July 6, 2026 so you should expect the next rating to be made available sometime around July 6, 2027.

While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a initiated with a price target of $0.00 to $38.00. The current price Avalo Therapeutics (AVTX) is trading at is $18.84, which is within the analyst’s predicted range.